Having trouble accessing articles? Reset your cache.

Brentuximab vedotin: Phase II data

Top-line data from a single-arm, open-label, international Phase II trial in 58 patients with relapsed or refractory ALCL showed that brentuximab vedotin produced an ORR of 86%. The median duration of response

Read the full 323 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE